Snake envenomation remains one of the most urgent toxicologic emergencies encountered in canine practice across North America. Dogs are disproportionately affected because of their outdoor activity, curiosity, and tendency to investigate snakes. Clinical severity varies widely depending on snake species, venom composition, bite location, venom dose, and time to treatment. Antivenom remains the foundation of treatment for clinically significant envenomation. Evolving evidence in veterinary emergency medicine is refining supportive care strategies and examining investigational adjunctive therapies. A mixed-breed dog, after being envenomated by an eastern diamondback rattlesnake, was in shock with hypofibrinogenemia and hemolysis. Photo courtesy Dr. Michael Schaer Understanding venom effects in dogs Pit vipers (family Crotalidae)—including rattlesnakes, copperheads, and cottonmouths—account for most venomous snakebites in North American dogs.1 Venom composition varies substantially between species and even between snakes of the same species, depending on geography, age, and season.2 Traditionally, pit viper venoms have been described as primarily cytotoxic and hemotoxic, causing local tissue injury, vascular permeability, coagulopathy, and shock. However, some North American rattlesnake populations, including Mojave rattlesnakes and certain timber rattlesnake populations, possess clinically important neurotoxicity.3 The absence of local findings may delay recognition of severe envenomation. Venom contains a complex mixture of enzymes and peptides that contribute to: Local tissue destruction and edema Hemorrhage and endothelial injury Thrombocytopenia and coagulopathy Myonecrosis and rhabdomyolysis Neurotoxicity in selected species Hypotension and shock Most bites in dogs involve the face, neck, or front legs. Initial stabilization and triage The priority in snakebite management is stabilization rather than species identification. Owners should be discouraged from handling or transporting dead snakes because reflex envenomation can occur after death. A smartphone photograph of the snake may help with identification. Recommended prehospital advice includes: Restricted activity Transporting immediately for veterinary evaluation Avoiding tourniquets, bandages, incisions and suction, ice packs, or electric shock These interventions have not demonstrated benefits and may worsen tissue injury. On presentation, clinicians should rapidly assess: Airway and respiratory status Cardiovascular perfusion Neurologic function Progression of swelling Evidence of coagulopathy or hemolysis Upper airway compromise is rare unless there is an intraoral or retrobulbar bite. Despite often dramatic swelling, facial bites rarely compromise the airway in dogs. However, stertorous breathing or an elevated PCO2 level indicates a rare case of respiratory compromise. Oxygen supplementation and advanced airway management may be necessary in those rare cases. The patient showing marked hemoglobinuria from severe hemolysis. Photo courtesy Dr. Michael Schaer Diagnostic evaluation The severity of local swelling does not necessarily predict systemic toxicity. Some neurotoxic rattlesnake envenomations may initially produce minimal local findings despite life-threatening systemic effects. Baseline diagnostics commonly include: CBC with platelet count Blood smear evaluation Serum biochemistry Coagulation testing Blood gas analysis in patients with neurotoxicity and possible hypoventilation Urinalysis Echinocytosis is a useful clue in canine envenomation and has been reported in a high proportion of cases involving pit vipers and coral snakes. Clinicians should also monitor for: Thrombocytopenia Hypofibrinogenemia Prolonged clotting times Hemolysis Pigmenturia (both myoglobin and hemoglobinuria are nephrotoxic) Acute kidney injury Elevated creatine kinase Serial monitoring is important because coagulopathy, hemolysis, and systemic deterioration may develop hours after presentation. Antivenom remains the cornerstone of therapy Antivenom remains the only specific treatment for clinically significant snake envenomation. Modern antivenom therapy can substantially improve outcomes by: Neutralizing circulating venom Reducing progression of tissue injury and pain Improving coagulopathy Limiting cardiovascular instability Potentially decreasing mortality Early administration is important. Experimental and clinical observations suggest outcomes worsen substantially when treatment is delayed several hours after envenomation, possibly because irreversible injury has already occurred or because antivenom is less effective once venom has distributed into tissues. Indications for antivenom treatment generally include progressive and systemic signs: Progressive swelling Hypotension or shock Coagulopathy Hemolysis Neurotoxicity Significant pain Rapid clinical progression Copperhead snake bites are often less severe than rattlesnake bites and may occasionally be managed conservatively, though this remains case-dependent. Practical antivenom administration considerations Antivenom is typically administered intravenously with close monitoring for hypersensitivity reactions. While true anaphylaxis is uncommon, such a reaction can occur, with higher rates reported with whole IgG than with F(ab’)2 antivenoms.4 Common recommendations include: Slow initial infusion rates, except for intra-arteriolar envenomation and rapid onset of shock Close observation during administration Immediate access to epinephrine (0.01 mg/kg IM) Monitoring for vomiting, urticaria, hyperemia, or hypotension Dose requirements depend more on venom load than patient size. Small dogs may therefore require the same number of vials as large dogs if venom exposure is substantial, as indicated by the severity of signs. Pretreatment with antihistamines remains controversial and is not recommended by the authors. Supportive care principles Supportive care remains critical even when antivenom is available. Intravenous crystalloids are central to management because venom-induced vascular permeability and third spacing can rapidly lead to hypovolemia. Severe cases may require aggressive crystalloid fluid resuscitation. Hetastarch is not recommended because of its interference with platelet function. Blood products are rarely indicated during the early stage (first 18-24 hours) of treatment; ample amounts of IV crystalloid fluids and antivenom are the primary initial recommended treatments. Opioids are the preferred treatment for pain. NSAIDs are typically avoided because of potential adverse effects on platelet function and renal perfusion. Fresh frozen plasma or whole blood may be indicated in severe coagulopathy or hemorrhage, although correction of venom-induced hemostatic abnormalities often depends on adequate antivenom therapy rather than transfusion alone. A beagle after coral snake envenomation was on life support because of respiratory failure from the phospholipase A2 neurotoxin. Photo courtesy Dr. Michael Schaer Emerging therapies: Investigational phospholipase A2 inhibition One emerging area of research involves small-molecule inhibitors targeting secretory phospholipase A2 (sPLA2), a major toxin component in many snake venoms. An investigational sPLA2 inhibitor has shown promising preclinical activity against several snake species.7 To date, seven dogs have been treated with severe eastern coral snake envenomation with both antivenom and the inhibitor, four with the IV inhibitor, and three with the oral inhibitor. All dogs recovered without requiring mechanical ventilation despite significant neurologic weakness, with substantial reductions in hospital length of stay and cost of care compared to historical controls. The results for the first three dogs have been published.8 At present, the sPLA2 inhibitor remains an experimental adjunctive therapy rather than standard care. Larger comparative veterinary studies are needed to establish whether phospholipase A2 inhibition improves outcomes beyond conventional antivenom-based management, and to characterize the benefit in dogs with crotalid envenomation. The beagle in recovery status. Photo courtesy Dr. Michael Schaer Ongoing controversies in management Several longstanding management controversies persist in veterinary snakebite care. Corticosteroids Routine corticosteroid administration is generally not recommended because evidence for benefit is lacking, and concerns remain regarding impaired wound healing and immunosuppression. Their use may still be considered in selected circumstances, such as refractory shock or Type 3 hypersensitivity reactions (serum sickness). Antibiotics Routine prophylactic antibiotics are also controversial. While tissue injury can be substantial, true wound infection appears less common than historically assumed. Antibiotic decisions should be individualized based on wound appearance, necrosis, contamination, and patient factors. In dogs with pit viper envenomation, our experience is that a secondary infection is usually evident by the third day of hospitalization. Prognosis Prognosis varies considerably depending on: Snake species Venom dose Bite location Time to treatment Availability of antivenom Development of respiratory failure or shock Advanced age and co-morbidities Most dogs treated promptly for pit viper envenomation survive. Prognosis worsens with delayed presentation, severe coagulopathy, and neurotoxicity. Extensive tissue necrosis often shows a remarkable tendency to heal over 12-16 weeks with conservative treatment without surgical interference. Coral snake envenomation may carry higher morbidity because of respiratory paralysis (See: “Coral snake envenomation presents unique challenges”), but aggressive supportive care can still produce favorable outcomes. Coral snake envenomation presents unique challenges Unlike pit vipers, coral snakes are elapids with predominantly neurotoxic venom. Eastern coral snake envenomation in dogs may produce: Progressive lower motor neuron paralysis Weakness and tetraparesis Bulbar dysfunction Hypoventilation Respiratory failure Hemolysis in approximately 40 percent of dogs5 Severe neurologic disease may develop despite subtle local signs, and with the dog initially being asymptomatic. Mechanical ventilation may be required in severe cases and can necessitate several days of intensive care. Published veterinary case series have reported prolonged hospitalization and substantial treatment costs in ventilated dogs.6 Coral snake antivenom remains standard therapy where available. Dogs that present with neuromuscular weakness will require intensive supportive care because antivenom may have limited ability to reverse established neuromuscular weakness. Looking ahead Snakebite management in dogs continues to evolve. Antivenom remains the foundation of treatment, but advances in toxin biology are opening new avenues for adjunctive therapies that may eventually make treatment simpler and reduce morbidity. For now, the most effective strategies remain early recognition, rapid stabilization, prompt antivenom administration when indicated, and meticulous supportive care. As emerging therapies continue to be investigated, veterinarians may eventually have additional tools available for one of veterinary emergency medicine’s most challenging toxicologic emergencies. Michael Schaer, DVM, Diplomate ACVIM, Diplomate ACVECC, is professor emeritus and adjunct professor in Emergency and Critical Care Medicine at the University of Florida College of Veterinary Medicine Small Animal Hospital. He has more than 50 years of experience as a clinician and teacher. Dr. Schaer serves on the board of directors of the North American Society of Toxinology and has published several papers, book chapters, and textbooks. Contact: Schaerm@ufl.edu Timothy F. Platts-Mills, MD, MSc, FACEP, is chief medical officer at Ophirex, Inc., where he leads the clinical development program for small-molecule therapeutics for snakebite envenoming. An emergency physician and clinical trialist with more than 20 years of experience, he has helped lead two international clinical trials evaluating varespladib for venomous snakebite treatment, including the Phase 2 BRAVO and BRAVIO studies in the United States and India. Contact: tim@ophirex.com References Doyle-Odenbach, Riley, et al. “Most Dogs and Cats Recovered within 5 Days of Discharge after Hospitalization Secondary to Crotalid (Pit Viper) Envenomation: A Survey-Based Study.” American Journal of Veterinary Research 87, no. 5 (May 1, 2026). https://doi.org/10.2460/ajvr.25.11.0392. Casewell, Nicholas R., et al. “Medically Important Differences in Snake Venom Composition Are Dictated by Distinct Postgenomic Mechanisms.” Proceedings of the National Academy of Sciences 111, no. 25 (June 9, 2014): 9205–10. https://doi.org/10.1073/pnas.1405484111. Seifert, Steven A., James O. Armitage, and Elda E. Sanchez. “Snake Envenomation.” New England Journal of Medicine 386, no. 1 (January 6, 2022): 68–78. https://doi.org/10.1056/nejmra2105228. Witsil, Amanda J., et al. “272 Cases of Rattlesnake Envenomation in Dogs: Demographics and Treatment Including Safety of F(AB′)2 Antivenom Use in 236 Patients.” Toxicon 105 (October 2015): 19–26. https://doi.org/10.1016/j.toxicon.2015.08.028. Sullivan, Jordan M., et al. “Retrospective Evaluation of Clinical and Clinicopathologic Findings, Case Management, and Outcome for Dogs and Cats Exposed to Micrurus Fulvius (Eastern Coral Snake): 92 Cases (2021–2022).” Toxins 16, no. 6 (May 27, 2024): 246. https://doi.org/10.3390/toxins16060246. https://www.ophirex.com/varespladib-for-animal-use/ Woliver, Cory, et al. “Phospholipase A2 Inhibitor May Shorten the Duration of Clinical Signs in the Treatment of Neurotoxicity Caused by Eastern Coral Snake (Micrurus Fulvius) Envenomation in 3 Dogs.” Journal of the American Veterinary Medical Association 263, no. 12 (December 1, 2025): 1–7. https://doi.org/10.2460/javma.25.04.0275.
